Hemogenyx Pharmaceuticals (LON:HEMO) Shares Up 4.9% - Should You Buy?

Key Points

• Shares were up 4.9%, trading as high as GBX 998 and last at GBX 976 on Monday, with volume of 13,050 shares which was down 58% from the average session volume of 30,921.
• Hemogenyx is a preclinical-stage biotech focused on blood-disease therapies, including a CDX bi-specific antibody for relapsed/refractory AML, a HEMO-CAR-T program, and stem-cell products for BM/HSC transplants.
• The company has a market capitalization of £62.7 million and negative earnings (P/E -4.23); its reported metrics (current ratio 0.43, quick ratio 6.72, debt-to-equity -440.54) reflect atypical and potentially volatile financials for a small, pre-revenue biotech.

Hemogenyx Pharmaceuticals Plc (LON:HEMO - )'s share price shot up 4.9% on Monday . The stock traded as high as GBX 998 and last traded at GBX 976. 13,050 shares were traded during trading, a decline of 58% from the average session volume of 30,921 shares. The stock had previously closed at GBX 930.15.

Hemogenyx Pharmaceuticals Trading Up 4.9%

The firm has a market capitalization of £62.71 million, a price-to-earnings ratio of -4.23 and a beta of 1.56. The company has a fifty day moving average price of GBX 1,001.93 and a two-hundred day moving average price of GBX 861.85. The company has a current ratio of 0.43, a quick ratio of 6.72 and a debt-to-equity ratio of -440.54.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.